Abstract
Progressive Supranuclear Palsy (PSP) has been used to denote a unifying disorder with progressive parkinsonism with early falls, vertical supranuclear gaze palsy, pseudobulbar dysfunction and cognitive decline. Over the last decade, heterogeneity of the disease into different clinical subtypes has been recognized in clinicopathological studies. Although neuroimaging features and laboratory findings may support the diagnosis, true biomarkers are still lacking in the clinical setting. Neuronal and glial tau positive aggregates are predominantly found in basal ganglia and brainstem, and the significant association of PSP with the common H1 tau haplotype likely points to a pathophysiological role of the tau protein in the disease process. Future genetic studies of familial cases and an ongoing genome-wide association study of large series of pathological-proven cases may reveal additional genetic factors in the near future.
Keywords: Progressive supranuclear palsy, review, diagnosis, neuropathology, genetics, Parkinson's disease, MAPT, hallucinations, tremor, dysautonomia, GABAergic cell loss, striatum, cholinergic, dopaminergic cell loss
Current Alzheimer Research
Title: Recent Advances in Progressive Supranuclear Palsy: A Review
Volume: 8 Issue: 3
Author(s): L. D. Kaat, W. Z. Chiu, A. J.W. Boon and J. C. van Swieten
Affiliation:
Keywords: Progressive supranuclear palsy, review, diagnosis, neuropathology, genetics, Parkinson's disease, MAPT, hallucinations, tremor, dysautonomia, GABAergic cell loss, striatum, cholinergic, dopaminergic cell loss
Abstract: Progressive Supranuclear Palsy (PSP) has been used to denote a unifying disorder with progressive parkinsonism with early falls, vertical supranuclear gaze palsy, pseudobulbar dysfunction and cognitive decline. Over the last decade, heterogeneity of the disease into different clinical subtypes has been recognized in clinicopathological studies. Although neuroimaging features and laboratory findings may support the diagnosis, true biomarkers are still lacking in the clinical setting. Neuronal and glial tau positive aggregates are predominantly found in basal ganglia and brainstem, and the significant association of PSP with the common H1 tau haplotype likely points to a pathophysiological role of the tau protein in the disease process. Future genetic studies of familial cases and an ongoing genome-wide association study of large series of pathological-proven cases may reveal additional genetic factors in the near future.
Export Options
About this article
Cite this article as:
D. Kaat L., Z. Chiu W., J.W. Boon A. and C. van Swieten J., Recent Advances in Progressive Supranuclear Palsy: A Review, Current Alzheimer Research 2011; 8 (3) . https://dx.doi.org/10.2174/156720511795563809
DOI https://dx.doi.org/10.2174/156720511795563809 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Knowledge on Molecular Components of Lewy Bodies Discloses Future Therapeutic Strategies in Parkinsons Disease
Current Drug Targets - CNS & Neurological Disorders Current Issues in the Use of fMRI-Based Neurofeedback to Relieve Psychiatric Symptoms
Current Pharmaceutical Design The SAMP8 Mouse: A Model to Develop Therapeutic Interventions for Alzheimers Disease
Current Pharmaceutical Design Effects of Yokukansan, a Japanese Kampo Medicine for Symptoms Associated Autism Spectrum Disorder
CNS & Neurological Disorders - Drug Targets Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs for the Prevention of Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies
Current Alzheimer Research Genetic Variations of the Hemostatic System as Risk Factors for Venous and Arterial Thrombotic Disease
Current Genomics Acid Sensing Ion Channels and Acid Nociception
Current Pharmaceutical Design Improvement in Hypertension Management with Pharmacological and Non- Pharmacological Approaches: Current Perspectives
Current Pharmaceutical Design When is a Proof-of-Concept (POC) not a POC? Pomaglumetad (LY2140023) as a Case Study for Antipsychotic Efficacy
Current Pharmaceutical Design Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Blocking the Link between Stimulus and Response at Previously Attended Locations: Evidence for Inhibitory Tagging Mechanism
Neuroscience and Biomedical Engineering (Discontinued) The Nun Study: Risk Factors for Pathology and Clinical-Pathologic Correlations
Current Alzheimer Research Geriatric Evaluation of Oncological Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Plasma Angiotensin-(1-7) is a Potential Biomarker for Alzheimer’s Disease
Current Neurovascular Research Genetic Variants and Oxidative Stress in Alzheimer’s Disease
Current Alzheimer Research A New “Era” for the α7-nAChR
Current Drug Targets Periodontal Pathogens and Neuropsychiatric Health
Current Topics in Medicinal Chemistry Application of Carbon Nanotubes In Drug Delivery of Non-cancerous Diseases: A Review
Current Pharmaceutical Design Potential Therapeutic Relevance of Adenosine A2B and A2A Receptors in the Central Nervous System
CNS & Neurological Disorders - Drug Targets